Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.

Anthraquinone-bridged diruthenium(II) complexes inhibit migration and invasion of human hepatocarcinoma MHCC97-H cells


Metastasis is a major health threat for most cancer patients, thus anti-metastasis treatments that reduce cell migration and invasion are critical for cancer treatment. In this study, four anthraquinone-bridged diruthenium(II) complexes, [(bpy)2Ru(L)Ru(bpy)2]4+ (Ru1, L = 1,4-bis(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)anthracene-9,10-dione); Ru2, L = 1,5-bis(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)anthracene-9,10-dione; Ru3, L = 2,6-bis(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)anthracene-9,10-dione; and Ru4, L = 2,7-bis(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)anthracene-9,10-dione) were synthesized and characterized. These Ru(II) complexes exhibited multi-targeted anti-metastatic propertiesagainst human hepatocarcinoma MHCC97-H cells that included the inhibition of migration and invasion. Further investigation of the intracellular mechanisms revealed that Ru(II) complexes suppressed the phosphorylation of ERK and AKT. Moreover, significant reduction of the extracellular and intracellular expression of the metastatic regulatory proteins MMP-2 and MMP-9 was also observed after Ru1-Ru4 treatment. In addition, these Ru(II) complexes negatively modulate the actin cytoskeleton by inhibiting Cdc42 protein expression, arresting the cells in the G2/M phase. The results indicate that ruthenium(II) complexes have potential as drug candidates for anti-metastatic therapies.

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 16 Mar 2017, accepted on 14 Apr 2017 and first published on 17 Apr 2017

Article type:
DOI: 10.1039/C7QI00149E
Citation: Inorg. Chem. Front., 2017, Accepted Manuscript
  •   Request permissions

    Anthraquinone-bridged diruthenium(II) complexes inhibit migration and invasion of human hepatocarcinoma MHCC97-H cells

    J. Wang, J. Kou, Z. Zhao, K. Qiu and H. Chao, Inorg. Chem. Front., 2017, Accepted Manuscript , DOI: 10.1039/C7QI00149E

Search articles by author